Back to Journals » Breast Cancer: Targets and Therapy » Volume 14 » default
![](https://www.dovepress.com/cr_data/cache/journal_image/69/cope/thumb_100_1000_100.jpg)
Breast Cancer: Targets and Therapy
ISSN: 1179-1314
- View all (495)
- Volume 16, 2024 (24)
- Volume 15, 2023 (79)
- Volume 14, 2022 (41)
- Volume 13, 2021 (58)
- Volume 12, 2020 (27)
- Volume 11, 2019 (32)
- Volume 10, 2018 (24)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Archive: Volume 14, 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Chromobox Family Proteins as Putative Biomarkers for Breast Cancer Management: A Preliminary Study Based on Bioinformatics Analysis and qRT-PCR Validation
Tian H, Zhao T, Li Y, Sun N, Ma D, Shi Q, Zhang G, Chen Q, Zhang K, Chen C, Zhang Y, Qi X
Breast Cancer: Targets and Therapy 2022, 14:515-535
Published Date: 30 December 2022
Whole Genome Sequencing of Single-Circulating Tumor Cell Ameliorates Unraveling Breast Cancer Heterogeneity
Li Y, Jiang X, Zhong M, Yu B, Yuan H
Breast Cancer: Targets and Therapy 2022, 14:505-513
Published Date: 28 December 2022
Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis
Liu J, Sun X, Du Q, Yao J, Dai M, Cheng Q, Xu H, Li Y, Liu X, Zhang M, Zhou Y, Yang Y
Breast Cancer: Targets and Therapy 2022, 14:491-504
Published Date: 21 December 2022
Factors Predicting Positive Sentinel Lymph Node Biopsy in Clinically Node-Negative Breast Cancer [Letter]
Zhang JY, Xu BH
Breast Cancer: Targets and Therapy 2022, 14:489-490
Published Date: 21 December 2022
Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
Zheng YZ, Li JY, Ning LW, Xie N
Breast Cancer: Targets and Therapy 2022, 14:475-487
Published Date: 21 December 2022
Advances in Single-Cell Sequencing Technology and Its Applications in Triple-Negative Breast Cancer
Li M, Yan T, Wang M, Cai Y, Wei Y
Breast Cancer: Targets and Therapy 2022, 14:465-474
Published Date: 14 December 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
Lang Y, Wu B, Liu X
Breast Cancer: Targets and Therapy 2022, 14:453-463
Published Date: 9 December 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Effect of Chemotherapy on the Gut Microbiome of Breast Cancer Patients During the First Year of Treatment
Wu AH, Vigen C, Tseng C, Garcia AA, Spicer D
Breast Cancer: Targets and Therapy 2022, 14:433-451
Published Date: 9 December 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
Yu Y, Wang J, Liao D, Zhang D, Li X, Jia Y, Kong F
Breast Cancer: Targets and Therapy 2022, 14:417-432
Published Date: 9 December 2022
Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
Li Y, Ma X, Zhao Z, Li L, Gao C, Liu D, Li B, Zhao B
Breast Cancer: Targets and Therapy 2022, 14:405-415
Published Date: 6 December 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Metformin Inducing the Change of Functional and Exhausted Phenotypic Tumor-Infiltrated Lymphocytes and the Correlation with JNK Signal Pathway in Triple-Negative Breast Cancer
Wang R, Li Y, Zhao Y, Shi F, Zhou Q, Wu J, Lyu S, Song Q
Breast Cancer: Targets and Therapy 2022, 14:391-403
Published Date: 2 December 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer
Shen J, Wang M, Li F, Yan H, Wang R, Zhou J
Breast Cancer: Targets and Therapy 2022, 14:375-389
Published Date: 30 November 2022
Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer
Almasri H, Erjan A, Abudawaba H, Ashouri K, Mheid S, Alnsour A, Abdel-Razeq H
Breast Cancer: Targets and Therapy 2022, 14:363-373
Published Date: 29 October 2022
Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial
Caputo R, Fabi A, Romagnoli E, Baldini E, Grasso D, Fenderico N, Michelotti A
Breast Cancer: Targets and Therapy 2022, 14:351-362
Published Date: 18 October 2022
Evaluating the Fragility of Long-Term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy Prescription in Early Breast Cancer: Pooled Data from 10 Randomised Clinical Trials
Davey MG, Kerin MJ
Breast Cancer: Targets and Therapy 2022, 14:343-350
Published Date: 17 October 2022
Development and Validation of an MRI Radiomics-Based Signature to Predict Histological Grade in Patients with Invasive Breast Cancer
Wang S, Wei Y, Li Z, Xu J, Zhou Y
Breast Cancer: Targets and Therapy 2022, 14:335-342
Published Date: 14 October 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Factors Predicting Positive Sentinel Lymph Node Biopsy in Clinically Node-Negative Breast Cancer
Alsumai TS, Alhazzaa N, Alshamrani A, Assiri S, Alhefdhi A
Breast Cancer: Targets and Therapy 2022, 14:323-334
Published Date: 11 October 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Involvement of Insulin-Like Growth Factor 2 Messenger Ribonucleic Acid-Binding Protein 2 in the Regulation of the Expression of Breast Cancer-Related Genes
Gao C, Li L, Jin X, Song X, Li H, Xu X, Dong C, Ma B
Breast Cancer: Targets and Therapy 2022, 14:311-322
Published Date: 10 October 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Notch Signaling Pathway Contributes to Angiogenesis and Tumor Immunity in Breast Cancer
Jiang N, Hu Y, Wang M, Zhao Z, Li M
Breast Cancer: Targets and Therapy 2022, 14:291-309
Published Date: 27 September 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Is Routine Intraoperative Frozen Section Analysis of Sentinel Lymph Nodes Necessary in Every Early-Stage Breast Cancer?
Lerttiendamrong B, Treeratanapun N, Vacharathit V, Tantiphlachiva K, Vongwattanakit P, Manasnayakorn S, Vongsaisuwon M
Breast Cancer: Targets and Therapy 2022, 14:281-290
Published Date: 19 September 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series
Cosar R, Sut N, Ozen A, Tastekin E, Topaloglu S, Cicin I, Nurlu D, Ozler T, Demir S, Yıldız G, Şenödeyici E, Uzal MC
Breast Cancer: Targets and Therapy 2022, 14:259-280
Published Date: 8 September 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Chloride Intracellular Channel 1 is a Potential Biomarker for Breast Cancer
Xia J, Wang Q, Ju F, Luo X, Wang F, Zhou Y, Huang H, Wang H, Bao X
Breast Cancer: Targets and Therapy 2022, 14:247-258
Published Date: 2 September 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A Scoping Review on the Status of Female Breast Cancer in Asia with a Special Focus on Nepal
Dhakal R, Noula M, Roupa Z, Yamasaki EN
Breast Cancer: Targets and Therapy 2022, 14:229-246
Published Date: 26 August 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Ovo Like Zinc Finger 2 (OVOL2) Suppresses Breast Cancer Stem Cell Traits and Correlates with Immune Cells Infiltration
Wu J, Luo D, Li S
Breast Cancer: Targets and Therapy 2022, 14:211-227
Published Date: 15 August 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes
Bari S, Boulware D, Li J, Loftus L, Soyano Muller A, Jameel Z, Khong H, Czerniecki BJ, Costa RLB
Breast Cancer: Targets and Therapy 2022, 14:199-210
Published Date: 6 August 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
miR-623 Targets Metalloproteinase-1 and Attenuates Extravasation of Brain Metastatic Triple-Negative Breast Cancer Cells
Hammash D, Mahfood M, Khoder G, Ahmed M, Tlili A, Hamoudi R, Harati R
Breast Cancer: Targets and Therapy 2022, 14:187-198
Published Date: 1 August 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Heart Sparing Radiotherapy Techniques in Breast Cancer: A Focus on Deep Inspiration Breath Hold
Stowe HB, Andruska ND, Reynoso F, Thomas M, Bergom C
Breast Cancer: Targets and Therapy 2022, 14:175-186
Published Date: 20 July 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer
Dhabhar B
Breast Cancer: Targets and Therapy 2022, 14:163-173
Published Date: 14 July 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Effect of Estrogen Receptor Status on Survival in Breast Cancer Patients in Ethiopia. Retrospective Cohort Study
Belete AM, Aynalem YA, Gemeda BN, Demelew TM, Shiferaw WS
Breast Cancer: Targets and Therapy 2022, 14:153-161
Published Date: 17 June 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Occult Invasive Lobular Carcinoma Presenting as an Axillary Skin Metastatic Lesion Underwent Neoadjuvant Endocrine Therapy and Surgical Resection: A Case Report and Review of Literature
Busbait S, Alkhalifa AM, Aljohani S, Alhaddad H
Breast Cancer: Targets and Therapy 2022, 14:145-152
Published Date: 31 May 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Predictive Effect of the 8th AJCC Pathological Prognostic Staging on the Benefit of Postmastectomy Radiotherapy in N2/N3 Breast Cancer
Yang SP, Zhou P, Lian CL, He ZY, Wu SG
Breast Cancer: Targets and Therapy 2022, 14:133-144
Published Date: 13 May 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Breast Cancer in Italy: Stage and Region Distribution
Mangone L, Bisceglia I, Michiara M, Musolino A, Mazzoleni G, Caldarella A, Minerba S, Cascone G, Bella F, Dinaro Y, Pau L, Pinto C
Breast Cancer: Targets and Therapy 2022, 14:125-131
Published Date: 29 April 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
Bagegni NA, Davis AA, Clifton KK, Ademuyiwa FO
Breast Cancer: Targets and Therapy 2022, 14:113-123
Published Date: 29 April 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
Parati MC, Pedersini R, Perego G, Reduzzi R, Savio T, Cabiddu M, Borgonovo K, Ghilardi M, Luciani A, Petrelli F
Breast Cancer: Targets and Therapy 2022, 14:101-111
Published Date: 12 April 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer
Kok VC, Wang CCN, Liao SH, Chen DL
Breast Cancer: Targets and Therapy 2022, 14:85-99
Published Date: 12 April 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Polyethyleneimine (PEI) as a Polymer-Based Co-Delivery System for Breast Cancer Therapy
Fahira AI, Amalia R, Barliana MI, Gatera VA, Abdulah R
Breast Cancer: Targets and Therapy 2022, 14:71-83
Published Date: 8 April 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
Landry KK, Lyon JL, Victoria KE, Changizzadeh PN, Cole BF, Pulluri B, Sikov WM, Wood ME
Breast Cancer: Targets and Therapy 2022, 14:63-70
Published Date: 15 March 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis
Verras GI, Tchabashvili L, Mulita F, Grypari IM, Sourouni S, Panagodimou E, Argentou MI
Breast Cancer: Targets and Therapy 2022, 14:41-61
Published Date: 12 March 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK
Breast Cancer: Targets and Therapy 2022, 14:25-39
Published Date: 1 March 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review
Maqbool M, Bekele F, Fekadu G
Breast Cancer: Targets and Therapy 2022, 14:15-24
Published Date: 11 January 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective
Kadamkulam Syriac A, Nandu NS, Leone JP
Breast Cancer: Targets and Therapy 2022, 14:1-13
Published Date: 10 January 2022